[go: up one dir, main page]

WO2000057919A3 - Particules artificielles a base de lipides induisant l'immunite a mediation cellulaire - Google Patents

Particules artificielles a base de lipides induisant l'immunite a mediation cellulaire Download PDF

Info

Publication number
WO2000057919A3
WO2000057919A3 PCT/CA2000/000319 CA0000319W WO0057919A3 WO 2000057919 A3 WO2000057919 A3 WO 2000057919A3 CA 0000319 W CA0000319 W CA 0000319W WO 0057919 A3 WO0057919 A3 WO 0057919A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
mediated immunity
inducing cell
based artificial
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2000/000319
Other languages
English (en)
Other versions
WO2000057919A2 (fr
Inventor
Masanobu Sugimoto
Max Arella
Yasuhiro Furuichi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sapientia Therapeutics Ltd
Original Assignee
Sapientia Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapientia Therapeutics Ltd filed Critical Sapientia Therapeutics Ltd
Priority to AU34125/00A priority Critical patent/AU3412500A/en
Priority to EP00912299A priority patent/EP1165142A2/fr
Publication of WO2000057919A2 publication Critical patent/WO2000057919A2/fr
Publication of WO2000057919A3 publication Critical patent/WO2000057919A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des particules artificielles immunogènes (1), leurs procédés de production et leurs applications. Ces particules immunogènes (1) renferment une matrice à base lipide (3), des glycolipides (5, 6) et des conjugués peptide-lipide (7, 8) incrustés dans la matrice (3). Ces particules (1) sont très efficaces dans l'induction de l'immunité à médiation cellulaire (IMC) lors de leur administration chez un hôte. Les particules immunogènes (1) peuvent être utilisées comme agents immunostimulants (notamment des vaccins) et comme agents immunothérapeutiques servant à prévenir et/ou traiter des maladies infectieuses et des cancers, maladies pour lesquelles les réponses IMC jouent un rôle important.
PCT/CA2000/000319 1999-03-25 2000-03-23 Particules artificielles a base de lipides induisant l'immunite a mediation cellulaire Ceased WO2000057919A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU34125/00A AU3412500A (en) 1999-03-25 2000-03-23 Lipid-based artificial particles inducing cell-mediated immunity
EP00912299A EP1165142A2 (fr) 1999-03-25 2000-03-23 Particules artificielles a base de lipides induisant l'immunite a mediation cellulaire

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27605799A 1999-03-25 1999-03-25
US09/276,057 1999-03-25

Publications (2)

Publication Number Publication Date
WO2000057919A2 WO2000057919A2 (fr) 2000-10-05
WO2000057919A3 true WO2000057919A3 (fr) 2001-02-08

Family

ID=23054967

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000319 Ceased WO2000057919A2 (fr) 1999-03-25 2000-03-23 Particules artificielles a base de lipides induisant l'immunite a mediation cellulaire

Country Status (3)

Country Link
EP (1) EP1165142A2 (fr)
AU (1) AU3412500A (fr)
WO (1) WO2000057919A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010084A2 (fr) * 2005-07-15 2007-01-25 Johannes Savolainen Oligosaccharides et polysaccharides immunostimulateurs et utilisations correspondantes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366058A2 (fr) * 1988-10-27 1990-05-02 Abbott Laboratories Dispositif de délivrance à libération contrôlée, procédé de préparation du dispositif et méthode d'utilisation du dispositif
WO1998016240A1 (fr) * 1996-10-15 1998-04-23 The Liposome Company, Inc. Conjugues de peptide-lipide, liposomes et apport de medicaments par des liposomes
US5951986A (en) * 1993-06-09 1999-09-14 Connaught Laboratories Limited Tandem synthetic HIV-1 peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366058A2 (fr) * 1988-10-27 1990-05-02 Abbott Laboratories Dispositif de délivrance à libération contrôlée, procédé de préparation du dispositif et méthode d'utilisation du dispositif
US5951986A (en) * 1993-06-09 1999-09-14 Connaught Laboratories Limited Tandem synthetic HIV-1 peptides
WO1998016240A1 (fr) * 1996-10-15 1998-04-23 The Liposome Company, Inc. Conjugues de peptide-lipide, liposomes et apport de medicaments par des liposomes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AIDS RESEARCH AND HUMAN RETROVIRUSES, (1994) 10 SUPPL 2 S99-103. REF: 14 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; GOULD-FOGERITE S ET AL: "Lipid matrix -based subunit vaccines: a structure-function approach to oral and parenteral immunization.", XP002150859, retrieved from STN Database accession no. 95169526 *
SUGIMOTO, MASANOBU ET AL: "Oligomannose-coated liposomes as an adjuvant for the induction of cell-mediated immunity", FEBS LETT. (1995), 363(1,2), 53-6, XP002150858 *

Also Published As

Publication number Publication date
EP1165142A2 (fr) 2002-01-02
AU3412500A (en) 2000-10-16
WO2000057919A2 (fr) 2000-10-05

Similar Documents

Publication Publication Date Title
IL145982A0 (en) Vaccines
GB0025577D0 (en) Vaccine
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
HUP0103100A3 (en) Immunogenic betha-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
DE60039754D1 (de) Polykationische karbohydrate als immunostimulierende mittel in impstoffen
EP1880735A3 (fr) Vaccin
EP2246067A3 (fr) Procédés destinés à susciter, améliorer et entretenir les réponses immunitaires contre des épitopes limités au CMH de classe I dans des buts prophylactiques ou thérapeutiques
AUPP807399A0 (en) Improved immunogenic lhrh composition and methods relating thereto
EP0914153B8 (fr) Vaccins dct-polio multivalents
PT2184071T (pt) Solubilização de polisacáridos capsulares e vacinas combinadas
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
WO2001034801A3 (fr) Vaccins contenant de la gelatine recombinante
PT1326633E (pt) Composição compreendendo micropartículas imunogénicas
SI1835939T1 (sl) Cepljenje na osnovi meningokoknih konjugatov
AU2457100A (en) Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
WO2001097841A3 (fr) Qs-21 et il-12 utilises comme combinaison d'adjuvants
AU2238597A (en) Iscom or iscom-matrix comprising a mucus targetting substance and optionally, an antigen
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
EP2272531A3 (fr) Intégration du vaccin conjugué de méningococcus
AU2151902A (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
AU5577201A (en) Immunogenic pneumococcal protein and vaccine compositions thereof
GB2370772B (en) Acellular immunogenic compositions and acellular vaccine compositions against bacillus anthracis
MY127452A (en) Vaccines.
WO2000057919A3 (fr) Particules artificielles a base de lipides induisant l'immunite a mediation cellulaire
AU5529599A (en) Vaccine compositions using antigens encapsulated within alginate microspheres for oral administration and preparation process thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000912299

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000912299

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000912299

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP